Medincell SA
PAR:MEDCL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/E
Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.
Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.
Valuation Scenarios
If P/E returns to its Industry Average (7.1), the stock would be worth €-4.29 (117% downside from current price).
| Scenario | P/E Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -41 | €24.68 |
0%
|
| Industry Average | 7.1 | €-4.29 |
-117%
|
| Country Average | 15.5 | €-9.33 |
-138%
|
Forward P/E
Today’s price vs future net income
| Today's Market Cap | Net Income | Forward P/E | ||
|---|---|---|---|---|
|
€805.1m
|
/ |
Oct 2025
€-19.9m
|
= |
|
|
€805.1m
|
/ |
Mar 2026
€-12m
|
= |
|
|
€805.1m
|
/ |
Mar 2027
€17.3m
|
= |
|
|
€805.1m
|
/ |
Mar 2028
€46.5m
|
= |
|
|
€805.1m
|
/ |
Mar 2029
€59.5m
|
= |
|
|
€805.1m
|
/ |
Mar 2030
€84.6m
|
= |
|
|
€805.1m
|
/ |
Mar 2031
€65.3m
|
= |
|
Forward P/E shows whether today’s P/E still looks high or low once future net income are taken into account.
Peer Comparison
| Market Cap | P/E | ||||
|---|---|---|---|---|---|
| FR |
|
Medincell SA
PAR:MEDCL
|
817m EUR | -41 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
883B USD | 42.8 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
553.5B USD | 26.3 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.3B GBP | 27.7 | |
| CH |
|
Novartis AG
SIX:NOVN
|
221.1B CHF | 20.7 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
270.2B USD | 14.8 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 12 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
151.8B USD | 19.5 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
122B USD | 17.3 |
Market Distribution
| Min | 0.2 |
| 30th Percentile | 11 |
| Median | 15.5 |
| 70th Percentile | 26.8 |
| Max | 3 102.9 |
Other Multiples
Medincell SA
Glance View
MedinCell SA is a pharmaceutical company, which engages in the development of injectable products in therapeutic areas. The company is headquartered in Jacou, Occitanie and currently employs 150 full-time employees. The company went IPO on 2018-10-08. The firm is focused on the development of therapeutic solutions with worldwide access. The firm works on both for-profit and non-profit projects, in collaboration with partners ranging from pharmaceutical corporations to physicians, from biotechnology firms to academics and foundations. Its range of products consists of three products in development phase: mdc-IRM, a subcutaneous injection in phase III clinical study for the treatment of schizophrenia; mdc-CWM, an intra-articular injection in phase II clinical study for the treatment of post-surgical pain and inflammation; mdc-TJK, a subcutaneous injection for the treatment of schizophrenia, as well as a number of other products that are in the research phase, such as mdc-WWM, which is a subcutaneous injection for contraception, and mdc-ELK, a subcutaneous injection for the treatment of depression, among others.
